4D Molecular Therapeutics Inc (NASDAQ: FDMT) established initial surge of 16.11% at $9.66, as the Stock market unbolted on Wednesday, before settling in for the price of $8.32 at the close. Taking a more long-term approach, FDMT posted a 52-week range of $2.23-$9.52.
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was -9.89%. Meanwhile, its Annual Earning per share during the time was -9.89%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -23.95%. This publicly-traded company’s shares outstanding now amounts to $46.70 million, simultaneously with a float of $42.62 million. The organization now has a market capitalization sitting at $451.14 million. At the time of writing, stock’s 50-day Moving Average stood at $6.96, while the 200-day Moving Average is $4.91.
4D Molecular Therapeutics Inc (FDMT) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the 4D Molecular Therapeutics Inc industry. 4D Molecular Therapeutics Inc’s current insider ownership accounts for 8.75%, in contrast to 82.01% institutional ownership. According to the most recent insider trade that took place on Sep 23 ’25, this organization’s Chief Legal Officer sold 2,407 shares at the rate of 8.00, making the entire transaction reach 19,256 in total value, affecting insider ownership by 7,596.
4D Molecular Therapeutics Inc (FDMT) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.89 per share during the current fiscal year.
4D Molecular Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -23.95% and is forecasted to reach -3.81 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -9.91% through the next 5 years, which can be compared against the -9.89% growth it accomplished over the previous five years trading on the market.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Trading Performance Indicators
Let’s observe the current performance indicators for 4D Molecular Therapeutics Inc (FDMT). It’s Quick Ratio in the last reported quarter now stands at 8.75. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 15038.02.
In the same vein, FDMT’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.71, a figure that is expected to reach -0.98 in the next quarter, and analysts are predicting that it will be -3.81 at the market close of one year from today.
Technical Analysis of 4D Molecular Therapeutics Inc (FDMT)
Now, what If we examine the latest scores posted by [4D Molecular Therapeutics Inc, FDMT]. During the last 5-days, its volume was lower the volume of 0.84 million it reported in year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 58.77% While, its Average True Range was 79.29.
Raw Stochastic average of 4D Molecular Therapeutics Inc (FDMT) in the period of the previous 100 days is set at 97.30%, which indicates a major rise in contrast to 94.66% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.63 that was higher than 0.42 volatility it exhibited in the past 100-days period.
